Skip to content
Disclosery

Aisling Capital Management LP

Follow

13F filer, CIK 1766721, NEW YORK, NY

Aisling Capital Management LP reported $478,916,332 across 13 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-10. Its ten largest share positions make up 99.57% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001766721-26-000001

Period
2025-12-31
Reported value
$479M
Holdings
13
Top 10 weight
99.57%
New
1
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
URGNnew+108,000$2.53M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
BBIOreduced-1,000,000-$76.5M
VERONA PHARMA PLCexited-615,352-$65.7M
NUVBexited-2,960,659-$11M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0001766721-26-000001, largest first. % of portfolio is the value over $478,916,332, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,068,125 shares; 2024Q4: 6,068,125 shares; 2025Q1: 6,068,125 shares; 2025Q2: 6,068,125 shares; 2025Q3: 6,089,611 shares; 2025Q4: 5,089,611 shares 5,089,611$389M81.29%-1,000,000Timeline
SNDXSYNDAX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,025,000 shares; 2024Q4: 1,025,000 shares; 2025Q1: 1,025,000 shares; 2025Q2: 1,316,806 shares; 2025Q3: 1,316,806 shares; 2025Q4: 1,316,806 shares 1,316,806$27.7M5.78%0Timeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,472,331 shares; 2024Q4: 1,472,331 shares; 2025Q1: 1,472,331 shares; 2025Q2: 1,472,331 shares; 2025Q3: 1,472,331 shares; 2025Q4: 1,472,331 shares 1,472,331$23.1M4.82%0Timeline
BCAXBICARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 568,919 shares; 2024Q4: 568,919 shares; 2025Q1: 568,919 shares; 2025Q2: 568,919 shares; 2025Q3: 568,919 shares; 2025Q4: 568,919 shares 568,919$9.57M2%0Timeline
CMPSCOMPASS PATHWAYS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 964,500 shares; 2024Q4: 964,500 shares; 2025Q1: 1,198,418 shares; 2025Q2: 1,198,418 shares; 2025Q3: 1,198,418 shares; 2025Q4: 1,198,418 shares 1,198,418$8.27M1.73%0Timeline
BBOTBRIDGEBIO ONCOLOGY THERAPEUTQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 564,625 shares; 2025Q4: 564,625 shares 564,625$7.07M1.48%0Timeline
CALCCALCIMEDICA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 521,114 shares; 2024Q4: 521,114 shares; 2025Q1: 521,114 shares; 2025Q2: 521,114 shares; 2025Q3: 521,114 shares; 2025Q4: 521,114 shares 521,114$3.43M0.72%0Timeline
SRRKSCHOLAR ROCK HLDG CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 77,031 shares; 2025Q4: 77,031 shares 77,031$3.39M0.71%0Timeline
BMEABIOMEA FUSION INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 798,757 shares; 2024Q4: 798,757 shares; 2025Q1: 798,757 shares; 2025Q2: 2,048,757 shares; 2025Q3: 2,048,757 shares; 2025Q4: 2,048,757 shares 2,048,757$2.54M0.53%0Timeline
URGNUROGEN PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 108,000 shares 108,000$2.53M0.53%newTimeline
ACRSACLARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 434,455 shares; 2024Q4: 434,455 shares; 2025Q1: 434,455 shares; 2025Q2: 434,455 shares; 2025Q3: 434,455 shares; 2025Q4: 434,455 shares 434,455$1.31M0.27%0Timeline
MRKRMARKER THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 314,286 shares; 2024Q4: 325,370 shares; 2025Q1: 325,370 shares; 2025Q2: 325,370 shares; 2025Q3: 325,370 shares; 2025Q4: 325,370 shares 325,370$485K0.1%0Timeline
OKURONKURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 88,607 shares; 2025Q1: 88,607 shares; 2025Q2: 88,607 shares; 2025Q3: 88,607 shares; 2025Q4: 88,607 shares 88,607$257K0.05%0Timeline

Sold out in Q4 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
VERONA PHARMA PLCVERONA PHARMA PLC615,352$65.7Mshares
NUVBNUVATION BIO INC2,960,659$11Mshares

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001766721-26-000001 base2026-02-10acceptance time not in the bulk data set